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Association between IL28B polymorphism and treatment response
in patients with genotype 4 chronic hepatitis C
To the Editor:
We read with interest the study by Asselah et al. published in
the Journal of Hepatology [1] on the impact of IL28B SNPs on
the outcome of antiviral therapy in HCV genotype 4 patients
showing a signiﬁcant and independent association between
the polymorphism in rs12979860 of the IL28B gene and the
treatment response in a cohort of 82 consecutive treatment-
naïve patients. In the discussion, the authors surprisingly state
that to the best of their knowledge this was the ﬁrst study to
examine this association in this speciﬁc group of patients with
HCV-4 infection.
In fact, we already published a study that shows this corre-
lation more than a year ago [2]. Apparently the authors missed
our well published study since they even do not quote it. In
our study, 102 treatment-naïve HCV-4 infected patients (91
male, 11 female; age: 40.6 ± 8.2; 99 Egyptian, 3 European;
advanced ﬁbrosis [METAVIR F3–4]: 33.3%) were investigated.
Together with the rs12979860, we also determined the
rs8099917 SNP. We showed a signiﬁcant association between
the beneﬁcial IL28B CC genotype and sustained virologic
response (SVR), rapid virologic response (RVR), and 24-h
decline in viral load after the ﬁrst dose of peginterferon. In a
multivariate logistic regression model adjusting for age, BMI,
baseline viral load, and advanced ﬁbrosis, we identiﬁed IL28B
genotype, advanced ﬁbrosis, and high baseline viral load as
independent pre-treatment risk factors for SVR (Table 1). Thus,
when RVR was included in the multivariate model, only RVR
(OR: 27.25, 95% CI: 5.981–124.19; p <0.0001) and advanced
ﬁbrosis (OR: 0.168, 95% CI: 0.042–0.669; p = 0.0115) remained
signiﬁcant.
Furthermore, we extended our observation to the early phase
of virus elimination. We showed a faster decline of HCV viral load
after 24 h in CC carriers in a subgroup analysis of 39 patients (CC
[n = 18]: 1.599 ± 0.589 log10 IU/ml, TC/TT [n = 21]: 0.766 ± 0.547
log10 IU/ml; p <0.001).
In summary, we presented more data in more patients than in
the study by Asselah, which is only conﬁrmatory and certainly
not novel information.
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Table 1. Univariate and multivariate logistic regression analysis of factors affecting SVR in patients with genotype 4.
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age (10 yr increment)
Advanced fibrosis (F3/4)
0.533 0.306-0.926 0.0256
BMI (1.0 kg/m² increment) 1.013 0.982-1.046 0.41
High baseline viral load (>800.000 IU/ml) 0.292 0.092-0.934 0.038 0.064 0.008-0.496 0.0085
0.278 0.104-0.744 0.011 0.209 0.066-0.660 0.0076
IL28B (T allele) 0.136 0.047-0.394 0.0002 0.124 0.030-0.505 0.0036
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HCV genotype 4 infection: A major medical need
To the Editor:
Indeed, genotype 4 (HCV-4) is the most frequent cause of chronic
hepatitis C in the Middle-East, and sub-Saharan Africa. It has
recently spread to Southern Europe, particularly among intrave-
nous drug users and immigrants [1]. HCV-4 is mainly found in
Egypt, the country with the highest prevalence of HCV worldwide
(15%), where HCV-4 represents 90% of all HCV cases. For geno-
type 4 infected patients, the most effective therapy to eradicate
Letters to the Editor
706 Journal of Hepatology 2012 vol. 57 j 699–711
Open access under CC BY-NC-ND license.
the virus remains a combination of pegylated interferon (PegIFN)
alpha and ribavirin. In this speciﬁc genotype 4 population, there
is a major medical need for studies on natural history, new treat-
ments, and predictors of response.
We performed a study in a well-characterized cohort of HCV-4
patients, to investigate the association of IL28B polymorphism
with response to treatment or liver disease severity [2]. In our
article, our well-characterized unique large cohort was deﬁned
based on its ethnic origin. In this cohort, three different ethnic
groups were represented with 70 (43%) Egyptians, 53 (32%) Euro-
peans, and 37 (23%) Sub-Saharan Africans. A liver biopsy was per-
formed in 160 patients, of whom 78 (49%) had a mild ﬁbrosis
(F0–F1) and 82 (51%) a moderate to severe ﬁbrosis (F2–F4).
We did not observed an association between ﬁbrosis stage
and response to treatment; however, the proportion of patients
with cirrhosis (F4) was relatively small (17.1%). Eighty-two
patients received 48 weeks of PegIFNa and ribavirin. Among
these, 43 patients (52%) obtained an SVR and 39 failed treatment
(28 (32%) obtained a non-response and 11 (16%) were relapsers).
Among our treated patients, the proportion of rs12979860 CC
was 26.8%; CT was 52.4%, and TT was 20.8%. Since in genotype
4 patients the treatment will remain PegIFN and ribavirin for sev-
eral years, IL28B polymorphism may remain an important associ-
ated factor with response. Another study performed in Italy gave
similar results with an association between IL28B polymorphism
and SVR [3]. Of 112 treated patients (98 males, 75 of Egyptian
descent, 26 with cirrhosis) 103 were included in the ﬁnal analy-
sis; ﬁve discontinued treatment for non-virologic reasons and
four did not consent to genetic testing. Twenty-four (23%) were
genotype CC, 65 (63%) CT, and 14 (14%) TT. Overall, 50 (49%)
achieved an SVR: 21 (88%) CC patients versus 29 (37%) CT/TT.
Further studies will be needed to demonstrate whether geno-
type 4-infected patients with good predictors of response, includ-
ing IL28B CC, may beneﬁt from shorten therapy.
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The impact of organ dysfunction in cirrhosis: Survival at a cost?
To the Editor:
We were delighted to read the recent study from Shawcross et al.
which has reported the ﬁndings of a large and robust prospective
dataset examining the outcomes of patients with cirrhosis and
acute organ dysfunction admitted to the Liver ICU at King’s
College Hospital, London over a 7-year period (2000–2007) [1].
The study population of 563 ﬁrst admissions represents the larg-
est cohort described in the literature to date. The reported ICU
(51%) and hospital (59%) mortality rates are comparable to those
quoted in the majority of published datasets in recent years.
Whilst unarguably higher than the ICU and hospital mortality
rates of unselected general ICU admissions nationally (20% and
30%) [2], they are still notably lower than those reported by some
of the earlier publications in this ﬁeld [3].
This complex and challenging patient cohort all too frequently
ﬁnd themselves the focus of negative clinical bias and prognostic
pessimism due to entrenched anecdotal experiences and health-
care provider perceptions regarding ‘self inﬂicted’ illness. It is
therefore important that studies such as these examine current
trends in outcome, after all, the incidence of chronic liver disease
related hospital admissions and overall mortality is rising in the
UK [4] and is a growing area of signiﬁcant public health concern.
Despite the quantitative success of this dataset, by virtue of its
specialist setting it represents a tertiary transplant centre experi-
ence. More relevant to non-transplant critical care centres, we
would like to draw your readers’ attention to the results of a
study performed in 2010, which reported on the outcomes of
patients with cirrhosis and critical illness from the general inten-
sive care units of two large non-transplant centres in London [5].
It suggested the hypothesis that the patient population seen out-
side of transplant centres present with a different clinical pheno-
type, and hence would demonstrate even better outcomes from
their critical illness episode. The study population of Shawcross
et al. was composed largely of in-patients already on the tertiary
liver wards (50%) or cases referred acutely from external second-
ary care centres (44%) who were deemed to require specialist
input. Only 6% (35/563) were admitted de novo via the emer-
gency department or ‘general’ wards from elsewhere within
King’s College Hospital. Table 1 shows the descriptive cohort data
from both studies.
Differences can be observed in the degree of hyperbilirubina-
emia and serum creatinine level between groups. CPS, MELD,
APACHE and SOFA were also more extreme in the tertiary centre
cohort. This could conceivably account for the observed
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